Guidant MADIT II Trial Could Support Doubling Of ICD-Eligible Population
This article was originally published in The Gray Sheet
Executive Summary
Favorable results of the Guidant-sponsored MADIT II trial could increase the U.S. patient population that could benefit from implantable cardioverter defibrillator therapy from 300,000 to about 600,000, Guidant says
You may also be interested in...
Mixed Results Of Zoll's LifeVest Trial Sparks Reaction From Cardiologists
Results of VEST, the first randomized, multi-center trial of Zoll's LifeVest wearable cardioverter defibrillator for prevention of sudden cardiac death following a heart attack, missed its primary endpoint, a reduction in sudden cardiac deaths. However, patients randomized to LifeVest had lower overall risk of mortality than the patients randomized to standard medical therapy. The conflicting results triggered a lot of discussion among cardiologists online.
Scully Backs Docs In ICD Coverage Decision Process; McClellan Weighs Cost
CMS Administrator Tom Scully is citing unresolved clinical questions raised by the pending ICD coverage decision as the reason for its potential delay beyond the June timeframe
Scully Backs Docs In ICD Coverage Decision Process; McClellan Weighs Cost
CMS Administrator Tom Scully is citing unresolved clinical questions raised by the pending ICD coverage decision as the reason for its potential delay beyond the June timeframe